| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biochemistry and Biophysics |
Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland 20892
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
| MATERIALS AND METHODS |
|---|
|
|
|---|
Cell Culture.
A2058 (human melanoma) and COS-1 (green monkey kidney) cell lines were maintained as described previously (10)
.
Construction of ATX/NPP2 Mutants and Preparation of Mutant Proteins.
Site-directed point mutations of ATX/NPP2 were made by overlap extension PCR methodology as described previously (11)
. ATX/NPP2 cDNA, derived from MDA 435 cells, was cloned into pcDNA3.1 vector (pcDNA3.atx/npp2) and used as a template. PCR was performed using the Platinum Pfx DNA polymerase (Invitrogen Life Technologies, Inc., Carlsbad, CA) and oligonucleotides designed for each mutant (Table 1)
. Each mutant plasmid was sequenced to confirm the presence of the mutation and the fidelity of the PCR amplification. COS-1 cells were transiently transfected with pcDNA3.atx/npp2 or with each mutant plasmid using LipofectAMINE 2000 reagent (Invitrogen Life Technologies, Inc.) per manufacturers protocol. A nonvector control was produced by adding appropriate medium and identical treatments but no vector to COS-1 cells. Each medium was partially purified with concanavalin A-agarose as described previously (12)
.
|
PDE and Lyso-PLD Assays.
Partially purified conditioned medium from transfected COS cells was adjusted to equal ATX/NPP2 protein concentrations based on the intensity of immunoblot signals. Twenty-µl samples (100-µl reaction volume) were incubated in DMEM-BSA at 37°C in the presence of 0.5 mM of either p-nitrophenyl-TMP (for PDE assays) or LPC (for lyso-PLD assays). DMEM-BSA was used to mimic the conditions of the motility assays. For determination of PDE activity, reactions were stopped after 30 min by the addition of 900 µl of 0.1 N NaOH, and the nitrophenol product was detected by reading the absorbance at 410 nm (A410 nm x 64 = nmol). To determine lyso-PLD activity, released choline was detected by a modification of the enzymatic photometric assay described previously (14
, 15)
. A 900-µl cocktail containing 50 mM Tris-HCl (pH 8), 5 mM CaCl2, 0.3 mM N-ethyl-N-(2-hydroxy-3-sulfopropyl)-m-toluidine (TOOS), 0.5 mM 4-aminoantipyrene (4-AAP), 5.3 units/ml horseradish peroxidase, and 2 units/ml choline oxidase were added to the 100-µl reaction mixture and were incubated for 15 min at 37°C. Absorbance was read at 555 nm and converted to nmol of choline by comparison with a choline standard curve.
Cell Motility Assays.
A2058 cells were prepared and used for motility assays as described previously in detail (16)
. Partially purified conditioned medium from transfected COS cells was adjusted to equal ATX/NPP2 protein concentrations based on the intensity of immunoblot signals. Migrated cells were counted under light microscopy at x200 (medium power field).
| RESULTS AND DISCUSSION |
|---|
|
|
|---|
Because histidines are crucial to catalysis in both of our enzyme models and many other phosphoreactive catalytic sites, most of the introduced mutations involved changes in histidine residues, with the exception being T210A. Three mutations were placed into the ATX/NPP2 homologues of histidines proposed to coordinate the binding of metal ions: H316Q, H360Q, and H475Q. Although ATX/NPP2 has no canonical HKD, mutations were created in those histidines from the two most similar sites: H587 (HxKxxxxE), mutated into H587Q, and H453 (HxxRKxxD), mutated into H453Q. The final two mutations were chosen because of their proximity to the PDE catalytic site to create H243Q and H298Q. The locations of these eight mutations relative to known domains in ATX/NPP2 are shown schematically in Fig. 1A
. The residues associated with PDE activity are shown in red, others are shown in blue.
|
Effect of Point Mutations on PDE and lyso-PLD Enzymatic Activities.
Each mutant ATX/NPP2 was tested for PDE and lyso-PLD activities, using well-established colorimetric assays: p-nitrophenyl-TMP hydrolysis for PDE (12)
and choline release from LPC for lyso-PLD (3)
. Wild-type ATX/NPP2 served as positive control, and partially purified conditioned medium from non-vector-transfected COS-1 cells as negative control in these experiments. For both types of assays, results were expressed as a percentage of wild-type activity.
As shown in Fig. 1C
, mutant ATX/NPP2s that were altered in the PDE-reactive center (T210A, H316Q, H360Q, and H475Q) possessed significantly reduced PDE activity compared with wild-type ATX/NPP2 (P < 0.01 for H316Q and H475Q; P < 0.001 for T210A and H360Q). This was an expected finding because Gijsberg et al. (9)
had found that mutations in the homologous amino acids of PC-1/NPP1 resulted in similarly reduced activity. In novel findings, these same four mutant ATX/NPP2s (T210A, H316Q, H360Q, and H475Q) also had greatly diminished lyso-PLD activity compared with wild-type ATX/NPP2 (P < 0.001 for all). In fact, these activity-negative forms of ATX/NPP2 were not significantly different from the nonvector control for the activity of either enzyme, even at substrate concentrations that were saturating for the activity-positive forms. This fact precludes comparison of substrate concentration dependence. In contrast, those ATX/NPP2 mutant proteins that most closely corresponded to the HKD motif (H587Q and H453Q) had PDE and lyso-PLD activities that were not significantly different from those of native autotaxin. Similarly, the ATX/NPP2 mutants chosen for their proximity to the PDE-reactive site (H243Q and H298Q) also retained the activities of both enzymes, which were not significantly different from the activity of native ATX/NPP2.
We have shown that the hydrolysis of LPC by ATX/NPP2 has structural requirements for threonine and histidine identical to those for nucleotide hydrolysis. Despite the similarity of substrates, phospholipids versus lysophospholipids, the PLD and lyso-PLD enzymes seem to use different catalytic strategies for the hydrolysis of phosphodiester bonds. The precise correspondence between the effects of four separate point mutations on both PDE and lyso-PLD activities strongly indicates the presence of a common enzymatic site in ATX/NPP2, suggesting that ATX/NPP2/lyso-LPD uses a common reaction mechanism for the hydrolysis of nucleotides and lysophospholipids.
Effect of Point Mutations on the Migration Responses of A2058 Cells.
To determine the effects of these same eight mutations on the capacity of the resulting ATX/NPP2s to stimulate motility, each was tested via a modified Boyden chamber assay for its capacity to induce a migration response in A2058 responder cells. Wild-type ATX/NPP2 served as the positive control in these experiments. Conditioned medium from non-vector-transfected COS-1 cells, as well as DMEM-BSA alone, served as negative controls. The result of a representative motility assay is shown in Fig. 2A
. The same four mutant ATX/NPP2s that lacked both PDE and lyso-PLD activity (T210A, H316Q, H360Q, and H475Q) also failed to stimulate motility (P < 0.001 compared with wild-type ATX/NPP2). These enzyme-negative mutants were essentially no different from the nonvector control. In contrast, the mutations that had no significant effect on any enzymatic activity (H243Q, H298Q, H453Q, and H587Q) induced a migration response that was equivalent to that of native autotaxin.
|
For the first time, we have shown that the capacity of mutant ATX/NPP2s to induce migration correlates directly with their capacity to hydrolyze both nucleotides and lysophospholipids. These data present a cogent argument that the enzyme reactive center of ATX/NPP2 must be intact for the protein to produce a migration response, strongly implying that this response results from its enzymatic products.
Adenosine Receptor Does Not Mediate ATX/NPP2 Migration Response.
The correlation of both PDE and lyso-LPD activities with the stimulation of a motile response raises the possibility that nucleotides might also be important to ATX/NPP2-stimulated motility. Platelets have been shown to release both adenosine nucleotides and LPC (17)
, providing a physiological mixture of alternative substrates. Tokumura et al. (4)
found that high concentrations (510 mM) of ATP or p-nitrophenyl-TMP inhibited choline release from LPC, suggesting the possibility of complex substrate interactions in the microenvironment of the cell. In addition, extracellular nucleosides and nucleotides are known to elicit numerous physiological responses by binding to specific membrane receptors. In A2058 cells, both adenosine and 5'-AMP elicit similar pertussis-toxin-sensitive migration responses, mediated by the A1 subclass of the P1 purinoceptor family (18)
.
We, therefore, tested the effect of the A1-specific adenosine analogue CPT on the migration response of A2058 cells to both native ATX/NPP2 and 5'-AMP. The results are shown in Fig. 3
. CPT completely blocked the 5'-AMP response (P < 0.001 for CPT treated versus untreated) but had no significant effect on ATX/NPP2-stimulated migration, indicating that the ATX/NPP2 response is independent of the adenosine A1 receptor. Although ATX/NPP2 possesses 5'-nucleotide PDE activity, the migration elicited by the product of this reaction, AMP, is independent of the motogenic effect of ATX/NPP2.
|
| FOOTNOTES |
|---|
1 To whom requests for reprints should be addressed, at Laboratory of Pathology, National Cancer Institute, NIH, Building 10, Room 2A33, 9000 Rockville Pike, Bethesda, MD 20892. Phone: (301) 496-1843; Fax: (301) 402-8911; E-mail: kohe{at}mail.nih.gov ![]()
2 The abbreviations used are: ATX, autotaxin; ATX/NPP2, autotaxin-NPP2; CPT, 1,3-dimethyl-8-cyclopentylxanthine; DMEM-BSA, DMEM with 0.1% (w/v) BSA; LPA, lysophosphatidic acid; LPC, lysophosphatidylcholine; NPP, nucleotide phosphodiesterase and pyrophosphatase; PDE, 5'-nucleotide phosphodiesterase; PLD, phospholipase D; lyso-PLD, lysophospholipase D. ![]()
Received 12/23/02. Accepted 3/ 5/03.
| REFERENCES |
|---|
|
|
|---|
vß3 mediates chemotactic and haptotactic motility in human melanoma cells through different signaling pathways. J. Biol. Chem., 271: 3247-3254, 1996.This article has been cited by other articles:
![]() |
A. Giganti, M. Rodriguez, B. Fould, N. Moulharat, F. Coge, P. Chomarat, J.-P. Galizzi, P. Valet, J.-S. Saulnier-Blache, J. A. Boutin, et al. Murine and Human Autotaxin {alpha}, {beta}, and {gamma} Isoforms: GENE ORGANIZATION, TISSUE DISTRIBUTION, AND BIOCHEMICAL CHARACTERIZATION J. Biol. Chem., March 21, 2008; 283(12): 7776 - 7789. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Ptaszynska, M. L. Pendrak, R. W. Bandle, M. L. Stracke, and D. D. Roberts Positive Feedback between Vascular Endothelial Growth Factor-A and Autotaxin in Ovarian Cancer Cells Mol. Cancer Res., March 1, 2008; 6(3): 352 - 363. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jansen, C. Stefan, J. W. M. Creemers, E. Waelkens, A. Van Eynde, W. Stalmans, and M. Bollen Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D J. Cell Sci., July 15, 2005; 118(14): 3081 - 3089. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. van Meeteren, P. Ruurs, E. Christodoulou, J. W. Goding, H. Takakusa, K. Kikuchi, A. Perrakis, T. Nagano, and W. H. Moolenaar Inhibition of Autotaxin by Lysophosphatidic Acid and Sphingosine 1-Phosphate J. Biol. Chem., June 3, 2005; 280(22): 21155 - 21161. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Clair, J. Aoki, E. Koh, R. W. Bandle, S. W. Nam, M. M. Ptaszynska, G. B. Mills, E. Schiffmann, L. A. Liotta, and M. L. Stracke Autotaxin Hydrolyzes Sphingosylphosphorylcholine to Produce the Regulator of Migration, Sphingosine-1-Phosphate Cancer Res., September 1, 2003; 63(17): 5446 - 5453. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |